Why the Painchek (ASX:PCK) share price lifted today

The Painchek (ASX: PCK) share price was up more than 4% at close of trade after the company released its quarterly report today.

Daniel Ewing

Born in Edinburgh, Scotland, Daniel moved to the Gold Coast, Australia at age 11. Nine years later he is in his third year of University at Monash in Melbourne. While starting out in a Science Degree, Daniel realised it wasn’t for him and promptly transferred to Commerce where he has developed a passion for the stock market. When not studying, Daniel can be most often found at the beach thanks to a passion for surfing.

Published January 22, 2021 5:57 pm AEDT

The Painchek Ltd (ASX: PCK) share price climbed today after the company provided the market with a positive quarterly update for December 2020.

Shares in the small cap healthcare company were trading 4.2% higher at 7.4 cents on close of trade today.

medical asx share price represented by doctor giving thumbs up — Image source: Getty Images

What is driving the Painchek share price

In today's release, the company reported continued growth in its aged care and initial entry into the hospital, home care and disability markets during the quarter ended 31 December.

In its core aged care market segment, Painchek delivered sales growth of 7% from the prior quarter. And with its global licences covering 71,318 beds, year on year (YoY) growth is up 123%. The company reported its domestic sales now reflect more than 30% of Australia's domestic aged care market share.

As a result, Painchek now has 884 aged care clients, up 133% YoY, and the forward looking revenue equates to more than $3 million annualised recurring revenue.

However it was not all smooth sailing for the company, with several large provider agreements delayed as a result of COVID-19 disruptions. Paincheck said these discussions have since been resumed in January.

Management comments

Painchek CEO Philip Daffas welcomed the update, saying:

While 2020 was challenging for many businesses, we successfully continued to deliver with significant sales growth. This included pivoting to a fully digital sales and delivery model that met the immediate needs of our clients, as well as establishing a new cost-effective global go-to-market model.

About the company

PainChek develops and commercialises medical device applications. This is aimed specifically at automating intelligent pain assessment of individuals who are unable to communicate their pain with carers (such as people in aged care facilities).

In particular, the company is involved in the provision of pain management and better medication for residents living with dementia and other communication difficulties. Painchek has already obtained regulatory clearance in Australia and Europe.

Automatic Renewal

By taking up this offer, you will also be enrolled in our auto-renewal program, which is our way of making your ongoing subscription easier by ensuring uninterrupted service. Don't worry, though – you're not locked in, and can cancel your auto-renewal at any time before each 'anniversary' date without question or penalty.